Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to get Screeners that run automatically with the results emailed to you! FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | More
 
or
Watchlist | Portfolio
Site News
Contact
Market:

Avacta Group Plc (AVCT.LN)

Avacta Group Plc (AVCT.LN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [LSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [LSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
First Patient Dosed in the US in Avacta’s AVA6000 Phase 1 Clinical Study Business Wire - Thu Apr 27, 2023

Avacta Group plc (AIM: AVCT), a life sciences company developing innovative, targeted oncology drugs and powerful diagnostics, announces that the first patient has been dosed in the US under its Investigational...

AVCT.LN : 43.255 (-0.56%)
AVCT : 0.5980 (-11.01%)
Avacta Announces First Patient Dosed in Fifth Cohort of AVA6000 Phase Ia Dose Escalation Study Business Wire - Wed Apr 5, 2023

Avacta Group plc (AIM: AVCT), a life sciences company developing innovative, targeted oncology drugs and powerful diagnostics, announces that the first patient has been dosed in the fifth cohort of the...

AVCT.LN : 43.255 (-0.56%)
AVCT : 0.5980 (-11.01%)
Avacta Appoints Karen Harrison as Chief Operating Officer for Therapeutics Division Business Wire - Tue Mar 28, 2023

Avacta Group plc (AIM: AVCT), a life sciences company developing innovative, targeted oncology drugs and powerful diagnostics, today announced the appointment of Karen Harrison as Chief Operating Officer...

AVCT.LN : 43.255 (-0.56%)
AVCT : 0.5980 (-11.01%)
Avacta Announces AVA6000 Receives Orphan Drug Designation From the US Food and Drug Administration Business Wire - Mon Sep 5, 2022

Avacta Group plc (AIM: AVCT), a clinical stage oncology drug company and developer of powerful diagnostics based on its innovative Affimer ® and pre|CISION™ platforms, announces that the US Food and...

AVCT.LN : 43.255 (-0.56%)
AVCT : 0.5980 (-11.01%)
LG Chem Renews License Triggering Payment to Avacta Business Wire - Thu Jun 30, 2022

Avacta Group plc (AIM: AVCT), a clinical stage biopharmaceutical company developing innovative cancer therapies and powerful diagnostics based on its proprietary Affimer ® and pre|CISION™ platforms,...

AVCT.LN : 43.255 (-0.56%)
AVCT : 0.5980 (-11.01%)
Avacta Announces AffyXell Joint Venture Milestone and Increased Equity Stake Business Wire - Wed Apr 13, 2022

Avacta Group plc (AIM: AVCT), a clinical stage oncology drug company and developer of powerful diagnostics based on its innovative Affimer® and pre|CISION™ platforms, is pleased to announce that a milestone...

AVCT.LN : 43.255 (-0.56%)
AVCT : 0.5980 (-11.01%)
Avacta Appoints Dr Christina Coughlin as Non-Executive Director Business Wire - Mon Mar 21, 2022

Avacta Group plc (AIM: AVCT), a clinical stage biopharmaceutical company developing innovative cancer therapies and powerful diagnostics based on its proprietary Affimer® and pre|CISION™ platforms announces...

AVCT.LN : 43.255 (-0.56%)
AVCT : 0.5980 (-11.01%)
Avacta Selects Second pre|CISION™ Pro-drug Candidate for Development Business Wire - Tue Jan 18, 2022

Avacta Group plc (AIM: AVCT), a clinical stage biopharmaceutical company developing innovative cancer therapies and powerful diagnostics based on its proprietary Affimer® and pre|CISION™ platforms announces...

AVCT.LN : 43.255 (-0.56%)
AVCT : 0.5980 (-11.01%)
Avacta Announces AffiDX® SARS-CoV-2 Antigen Lateral Flow Test Receives CE Mark for Consumer Self-Testing Business Wire - Wed Dec 22, 2021

Avacta Group plc (AIM: AVCT), a clinical stage biopharmaceutical company developing innovative cancer therapies and powerful diagnostics based on its proprietary Affimer® and pre|CISION™ platforms,...

AVCT.LN : 43.255 (-0.56%)
AVCT : 0.5980 (-11.01%)
Avacta Announces AffiDx® SARS-CoV-2 Antigen Lateral Flow Test Detects the Omicron Variant Business Wire - Wed Dec 15, 2021

Avacta Group plc (AIM: AVCT), a clinical stage biopharmaceutical company developing innovative cancer therapies and powerful diagnostics based on its proprietary Affimer® and pre|CISION™ platforms is...

AVCT.LN : 43.255 (-0.56%)
AVCT : 0.5980 (-11.01%)

Barchart Exclusives

Is It Too Late to Buy This Energy Dividend Stock at New Highs? Barchart - Thu May 16, 6:30PM CDT
Here's a closer look at whether Constellation Energy's recent surge to record highs presents a lucrative opportunity to buy into the bullish momentum, or whether investors should practice caution at the current valuation. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar

[[ data.userDate ]]
[[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' ]] [[ zone ]]
Reserve Your Spot